Comparing NOVOZYMES A/S/S (OTCMKTS:NVZMY) and Twist Bioscience (OTCMKTS:TWST)

Share on StockTwits

NOVOZYMES A/S/S (OTCMKTS:NVZMY) and Twist Bioscience (NASDAQ:TWST) are both basic materials companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Profitability

This table compares NOVOZYMES A/S/S and Twist Bioscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NOVOZYMES A/S/S 21.08% 26.73% 14.85%
Twist Bioscience -204.63% -168.45% -61.41%

Institutional and Insider Ownership

0.2% of NOVOZYMES A/S/S shares are owned by institutional investors. Comparatively, 42.6% of Twist Bioscience shares are owned by institutional investors. 29.4% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dividends

NOVOZYMES A/S/S pays an annual dividend of $0.50 per share and has a dividend yield of 1.1%. Twist Bioscience does not pay a dividend. NOVOZYMES A/S/S pays out 28.6% of its earnings in the form of a dividend.

Valuation & Earnings

This table compares NOVOZYMES A/S/S and Twist Bioscience’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NOVOZYMES A/S/S $2.28 billion 6.11 $511.00 million $1.75 26.81
Twist Bioscience $25.43 million 28.63 -$71.23 million ($25.51) -0.88

NOVOZYMES A/S/S has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than NOVOZYMES A/S/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for NOVOZYMES A/S/S and Twist Bioscience, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NOVOZYMES A/S/S 1 1 2 0 2.25
Twist Bioscience 0 1 3 0 2.75

Twist Bioscience has a consensus target price of $26.33, suggesting a potential upside of 17.73%. Given Twist Bioscience’s stronger consensus rating and higher possible upside, analysts plainly believe Twist Bioscience is more favorable than NOVOZYMES A/S/S.

Summary

NOVOZYMES A/S/S beats Twist Bioscience on 8 of the 15 factors compared between the two stocks.

NOVOZYMES A/S/S Company Profile

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising bioscouring, bleach clean-up, desizing, denim finishing and abrasion, and biopolishing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rtrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research and development, production, marketing, and sale of a portfolio of probiotic products. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has a collaboration agreement with Pandion Therapeutics, Inc. to apply its antibody optimization platform for a targeting arm of a bispecific antibody. The company was founded in 2013 and is headquartered in San Francisco, California.

Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ethersocial  Hits Market Cap of $204,268.00
Ethersocial Hits Market Cap of $204,268.00
Pascal  Price Tops $0.0551 on Exchanges
Pascal Price Tops $0.0551 on Exchanges
Comparing NOVOZYMES A/S/S  and Twist Bioscience
Comparing NOVOZYMES A/S/S and Twist Bioscience
Citigroup Boosts Camden Property Trust  Price Target to $115.00
Citigroup Boosts Camden Property Trust Price Target to $115.00
CVS Health  Stock Rating Reaffirmed by UBS Group
CVS Health Stock Rating Reaffirmed by UBS Group
TiVo  Lowered to “Hold” at BidaskClub
TiVo Lowered to “Hold” at BidaskClub


© 2006-2019 Ticker Report